Parkinson's disease: 10 years of progress, 1997–2007
Identifieur interne : 000021 ( Main/Corpus ); précédent : 000020; suivant : 000022Parkinson's disease: 10 years of progress, 1997–2007
Auteurs : Stanley FahnSource :
- Movement Disorders [ 0885-3185 ] ; 2010.
English descriptors
- KwdEn :
Abstract
Many people with Parkinson's disease (PD) and their family members ask their physicians “What is happening in research on Parkinson's disease? Is there anything new?” As the initial speaker at the symposium organized by the Parkinson's Disease Foundation in celebration of its 50th anniversary, I sought to address these questions, focusing on research published between the years 1997 and 2007. I cataloged the advances I considered most important in the field, recognizing my viewpoint is a subjective one and most likely differs from similar listings that others would put together. Space limitation allows me to discuss only a tiny fraction of the remarkable new findings that have been discovered during this 10‐year span. Nevertheless, I expect the readers of this summation of advances in the field to be as impressed as I am on the wealth, breadth, and excitement stirring in the field of PD research. Included in this overview are highlights in both laboratory science and clinical science of PD research. In the former category are advances in knowledge on the genetics of PD; potential etiologic and pathogenic causes, especially the better understanding of endogenous factors within dopaminergic neurons; pathologic changes including deposition of alpha‐synuclein aggregates; and the consequences of altered alpha‐synuclein on the degradation of proteins by both the ubiquitin‐proteasomal pathway and the lysosome. Clinical science has also been very active and impressively productive with important clinical advances. In this category are new information on the epidemiology of PD, including awareness of additional factors (besides smoking) that might slow the onset and worsening of PD, such as caffeine and urate; neuroimaging with positron emission tomography and single photon emission tomography; keener awareness of nonmotor features of PD and their impact on quality of life for the persons with PD and their family; recognition of behavioral complications of medications utilized to treat PD, such as impulse control problems; appreciation of the natural history of PD with the increasing impairments as the disease relentlessly worsens over time; the many controlled clinical trials attempting to slow the progression of the disease and to provide new symptomatic therapies; and surgical approaches to alleviate symptoms and progression, including cellular and gene therapy as well as deep brain stimulation. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22796
Links to Exploration step
ISTEX:FBDBCDC2B8E5271B76D0026C202293F30969C97FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinson's disease: 10 years of progress, 1997–2007</title><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><affiliation><mods:affiliation>Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FBDBCDC2B8E5271B76D0026C202293F30969C97F</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22796</idno><idno type="url">https://api.istex.fr/document/FBDBCDC2B8E5271B76D0026C202293F30969C97F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000021</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parkinson's disease: 10 years of progress, 1997–2007</title><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><affiliation><mods:affiliation>Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010">2010</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="page" from="S2">S2</biblScope><biblScope unit="page" to="S14">S14</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">FBDBCDC2B8E5271B76D0026C202293F30969C97F</idno><idno type="DOI">10.1002/mds.22796</idno><idno type="ArticleID">MDS22796</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>epidemiology</term><term>genetics</term><term>imaging</term><term>pathogenesis</term><term>research</term><term>therapy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Many people with Parkinson's disease (PD) and their family members ask their physicians “What is happening in research on Parkinson's disease? Is there anything new?” As the initial speaker at the symposium organized by the Parkinson's Disease Foundation in celebration of its 50th anniversary, I sought to address these questions, focusing on research published between the years 1997 and 2007. I cataloged the advances I considered most important in the field, recognizing my viewpoint is a subjective one and most likely differs from similar listings that others would put together. Space limitation allows me to discuss only a tiny fraction of the remarkable new findings that have been discovered during this 10‐year span. Nevertheless, I expect the readers of this summation of advances in the field to be as impressed as I am on the wealth, breadth, and excitement stirring in the field of PD research. Included in this overview are highlights in both laboratory science and clinical science of PD research. In the former category are advances in knowledge on the genetics of PD; potential etiologic and pathogenic causes, especially the better understanding of endogenous factors within dopaminergic neurons; pathologic changes including deposition of alpha‐synuclein aggregates; and the consequences of altered alpha‐synuclein on the degradation of proteins by both the ubiquitin‐proteasomal pathway and the lysosome. Clinical science has also been very active and impressively productive with important clinical advances. In this category are new information on the epidemiology of PD, including awareness of additional factors (besides smoking) that might slow the onset and worsening of PD, such as caffeine and urate; neuroimaging with positron emission tomography and single photon emission tomography; keener awareness of nonmotor features of PD and their impact on quality of life for the persons with PD and their family; recognition of behavioral complications of medications utilized to treat PD, such as impulse control problems; appreciation of the natural history of PD with the increasing impairments as the disease relentlessly worsens over time; the many controlled clinical trials attempting to slow the progression of the disease and to provide new symptomatic therapies; and surgical approaches to alleviate symptoms and progression, including cellular and gene therapy as well as deep brain stimulation. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Stanley Fahn MD</name><affiliations><json:string>Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>research</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>genetics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pathogenesis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>epidemiology</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>imaging</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>therapy</value></json:item></subject><articleId><json:string>MDS22796</json:string></articleId><language><json:string>eng</json:string></language><abstract>Many people with Parkinson's disease (PD) and their family members ask their physicians “What is happening in research on Parkinson's disease? Is there anything new?” As the initial speaker at the symposium organized by the Parkinson's Disease Foundation in celebration of its 50th anniversary, I sought to address these questions, focusing on research published between the years 1997 and 2007. I cataloged the advances I considered most important in the field, recognizing my viewpoint is a subjective one and most likely differs from similar listings that others would put together. Space limitation allows me to discuss only a tiny fraction of the remarkable new findings that have been discovered during this 10‐year span. Nevertheless, I expect the readers of this summation of advances in the field to be as impressed as I am on the wealth, breadth, and excitement stirring in the field of PD research. Included in this overview are highlights in both laboratory science and clinical science of PD research. In the former category are advances in knowledge on the genetics of PD; potential etiologic and pathogenic causes, especially the better understanding of endogenous factors within dopaminergic neurons; pathologic changes including deposition of alpha‐synuclein aggregates; and the consequences of altered alpha‐synuclein on the degradation of proteins by both the ubiquitin‐proteasomal pathway and the lysosome. Clinical science has also been very active and impressively productive with important clinical advances. In this category are new information on the epidemiology of PD, including awareness of additional factors (besides smoking) that might slow the onset and worsening of PD, such as caffeine and urate; neuroimaging with positron emission tomography and single photon emission tomography; keener awareness of nonmotor features of PD and their impact on quality of life for the persons with PD and their family; recognition of behavioral complications of medications utilized to treat PD, such as impulse control problems; appreciation of the natural history of PD with the increasing impairments as the disease relentlessly worsens over time; the many controlled clinical trials attempting to slow the progression of the disease and to provide new symptomatic therapies; and surgical approaches to alleviate symptoms and progression, including cellular and gene therapy as well as deep brain stimulation. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>7</keywordCount><abstractCharCount>2465</abstractCharCount><pdfWordCount>8210</pdfWordCount><pdfCharCount>54646</pdfCharCount><pdfPageCount>13</pdfPageCount><abstractWordCount>370</abstractWordCount></qualityIndicators><title>Parkinson's disease: 10 years of progress, 1997–2007</title><genre><json:string>article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>13</total><last>S14</last><first>S2</first></pages><issn><json:string>0885-3185</json:string></issn><issue>S1</issue><author><json:item><name>Fahn Stanley MD</name></json:item><json:item><name>Marder Karen MD</name></json:item><json:item><name>Côté Lucien MD</name></json:item><json:item><name>Reich Stephen G. MD</name></json:item></author><subject><json:item><value>Introduction</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.22796</json:string></doi><id>FBDBCDC2B8E5271B76D0026C202293F30969C97F</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/FBDBCDC2B8E5271B76D0026C202293F30969C97F/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/FBDBCDC2B8E5271B76D0026C202293F30969C97F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/FBDBCDC2B8E5271B76D0026C202293F30969C97F/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Parkinson's disease: 10 years of progress, 1997–2007</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: None to report.</note><note type="content">*On the occasion of the Parkinson's Disease Foundation's 50th Anniversary Educational Symposium, October 11–12, 2007, New York, NY</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Parkinson's disease: 10 years of progress, 1997–2007</title><author><persName><forename type="first">Stanley</forename><surname>Fahn</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Neurological Institute, 710 West 168th Street, New York, NY 10032</p></note><affiliation>Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="page" from="S2">S2</biblScope><biblScope unit="page" to="S14">S14</biblScope></imprint></monogr><idno type="istex">FBDBCDC2B8E5271B76D0026C202293F30969C97F</idno><idno type="DOI">10.1002/mds.22796</idno><idno type="ArticleID">MDS22796</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Many people with Parkinson's disease (PD) and their family members ask their physicians “What is happening in research on Parkinson's disease? Is there anything new?” As the initial speaker at the symposium organized by the Parkinson's Disease Foundation in celebration of its 50th anniversary, I sought to address these questions, focusing on research published between the years 1997 and 2007. I cataloged the advances I considered most important in the field, recognizing my viewpoint is a subjective one and most likely differs from similar listings that others would put together. Space limitation allows me to discuss only a tiny fraction of the remarkable new findings that have been discovered during this 10‐year span. Nevertheless, I expect the readers of this summation of advances in the field to be as impressed as I am on the wealth, breadth, and excitement stirring in the field of PD research. Included in this overview are highlights in both laboratory science and clinical science of PD research. In the former category are advances in knowledge on the genetics of PD; potential etiologic and pathogenic causes, especially the better understanding of endogenous factors within dopaminergic neurons; pathologic changes including deposition of alpha‐synuclein aggregates; and the consequences of altered alpha‐synuclein on the degradation of proteins by both the ubiquitin‐proteasomal pathway and the lysosome. Clinical science has also been very active and impressively productive with important clinical advances. In this category are new information on the epidemiology of PD, including awareness of additional factors (besides smoking) that might slow the onset and worsening of PD, such as caffeine and urate; neuroimaging with positron emission tomography and single photon emission tomography; keener awareness of nonmotor features of PD and their impact on quality of life for the persons with PD and their family; recognition of behavioral complications of medications utilized to treat PD, such as impulse control problems; appreciation of the natural history of PD with the increasing impairments as the disease relentlessly worsens over time; the many controlled clinical trials attempting to slow the progression of the disease and to provide new symptomatic therapies; and surgical approaches to alleviate symptoms and progression, including cellular and gene therapy as well as deep brain stimulation. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>research</term></item><item><term>genetics</term></item><item><term>pathogenesis</term></item><item><term>epidemiology</term></item><item><term>imaging</term></item><item><term>therapy</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Introduction</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-05-28">Received</change><change when="2009-08-21">Registration</change><change when="2010">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/FBDBCDC2B8E5271B76D0026C202293F30969C97F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="5"><doi origin="wiley" registered="yes">10.1002/mds.v25.1s</doi><titleGroup><title type="specialIssueTitle">Frontiers of Science and Clinical Advances in Quality of Life in Parkinson's Disease</title></titleGroup><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">S1</numbering></numberingGroup><creators><creator xml:id="sped1" creatorRole="sponsoringEditor"><personName><givenNames>Fahn</givenNames><familyName>Stanley</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped2" creatorRole="sponsoringEditor"><personName><givenNames>Marder</givenNames><familyName>Karen</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped3" creatorRole="sponsoringEditor"><personName><givenNames>Côté</givenNames><familyName>Lucien</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped4" creatorRole="sponsoringEditor"><personName><givenNames>Reich</givenNames><familyName>Stephen G.</familyName><degrees>MD</degrees></personName></creator></creators><coverDate startDate="2010">2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="2" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22796</doi><idGroup><id type="unit" value="MDS22796"></id></idGroup><countGroup><count type="pageTotal" number="13"></count></countGroup><titleGroup><title type="articleCategory">Introduction</title><title type="tocHeading1">Introduction</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2009-05-28"></event><event type="manuscriptAccepted" date="2009-08-21"></event><event type="firstOnline" date="2010-02-25"></event><event type="publishedOnlineFinalForm" date="2010-02-25"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4 mode:FullText" date="2010-12-14"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">S2</numbering><numbering type="pageLast">S14</numbering></numberingGroup><correspondenceTo>Neurological Institute, 710 West 168th Street, New York, NY 10032</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22796.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="6"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="145"></count><count type="wordTotal" number="9117"></count></countGroup><titleGroup><title type="main" xml:lang="en">Parkinson's disease: 10 years of progress, 1997–2007<link href="#fn1"></link> <link href="#fn2"></link></title><title type="short" xml:lang="en">PD: 10 Years of Progress, 1997–2007</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Stanley</givenNames><familyName>Fahn</familyName><degrees>MD</degrees></personName><contactDetails><email>sf1@columbia.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">research</keyword><keyword xml:id="kwd3">genetics</keyword><keyword xml:id="kwd4">pathogenesis</keyword><keyword xml:id="kwd5">epidemiology</keyword><keyword xml:id="kwd6">imaging</keyword><keyword xml:id="kwd7">therapy</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Many people with Parkinson's disease (PD) and their family members ask their physicians “What is happening in research on Parkinson's disease? Is there anything new?” As the initial speaker at the symposium organized by the Parkinson's Disease Foundation in celebration of its 50th anniversary, I sought to address these questions, focusing on research published between the years 1997 and 2007. I cataloged the advances I considered most important in the field, recognizing my viewpoint is a subjective one and most likely differs from similar listings that others would put together. Space limitation allows me to discuss only a tiny fraction of the remarkable new findings that have been discovered during this 10‐year span. Nevertheless, I expect the readers of this summation of advances in the field to be as impressed as I am on the wealth, breadth, and excitement stirring in the field of PD research. Included in this overview are highlights in both laboratory science and clinical science of PD research. In the former category are advances in knowledge on the genetics of PD; potential etiologic and pathogenic causes, especially the better understanding of endogenous factors within dopaminergic neurons; pathologic changes including deposition of alpha‐synuclein aggregates; and the consequences of altered alpha‐synuclein on the degradation of proteins by both the ubiquitin‐proteasomal pathway and the lysosome. Clinical science has also been very active and impressively productive with important clinical advances. In this category are new information on the epidemiology of PD, including awareness of additional factors (besides smoking) that might slow the onset and worsening of PD, such as caffeine and urate; neuroimaging with positron emission tomography and single photon emission tomography; keener awareness of nonmotor features of PD and their impact on quality of life for the persons with PD and their family; recognition of behavioral complications of medications utilized to treat PD, such as impulse control problems; appreciation of the natural history of PD with the increasing impairments as the disease relentlessly worsens over time; the many controlled clinical trials attempting to slow the progression of the disease and to provide new symptomatic therapies; and surgical approaches to alleviate symptoms and progression, including cellular and gene therapy as well as deep brain stimulation. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: None to report.</p></note><note xml:id="fn2"><p>On the occasion of the Parkinson's Disease Foundation's 50th Anniversary Educational Symposium, October 11–12, 2007, New York, NY</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Parkinson's disease: 10 years of progress, 1997–2007</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>PD: 10 Years of Progress, 1997–2007</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Parkinson's disease: 10 years of progress, 1997–2007</title></titleInfo><name type="personal"><namePart type="given">Stanley</namePart><namePart type="family">Fahn</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA</affiliation><description>Correspondence: Neurological Institute, 710 West 168th Street, New York, NY 10032</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010</dateIssued><dateCaptured encoding="w3cdtf">2009-05-28</dateCaptured><dateValid encoding="w3cdtf">2009-08-21</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">6</extent><extent unit="tables">3</extent><extent unit="references">145</extent><extent unit="words">9117</extent></physicalDescription><abstract lang="en">Many people with Parkinson's disease (PD) and their family members ask their physicians “What is happening in research on Parkinson's disease? Is there anything new?” As the initial speaker at the symposium organized by the Parkinson's Disease Foundation in celebration of its 50th anniversary, I sought to address these questions, focusing on research published between the years 1997 and 2007. I cataloged the advances I considered most important in the field, recognizing my viewpoint is a subjective one and most likely differs from similar listings that others would put together. Space limitation allows me to discuss only a tiny fraction of the remarkable new findings that have been discovered during this 10‐year span. Nevertheless, I expect the readers of this summation of advances in the field to be as impressed as I am on the wealth, breadth, and excitement stirring in the field of PD research. Included in this overview are highlights in both laboratory science and clinical science of PD research. In the former category are advances in knowledge on the genetics of PD; potential etiologic and pathogenic causes, especially the better understanding of endogenous factors within dopaminergic neurons; pathologic changes including deposition of alpha‐synuclein aggregates; and the consequences of altered alpha‐synuclein on the degradation of proteins by both the ubiquitin‐proteasomal pathway and the lysosome. Clinical science has also been very active and impressively productive with important clinical advances. In this category are new information on the epidemiology of PD, including awareness of additional factors (besides smoking) that might slow the onset and worsening of PD, such as caffeine and urate; neuroimaging with positron emission tomography and single photon emission tomography; keener awareness of nonmotor features of PD and their impact on quality of life for the persons with PD and their family; recognition of behavioral complications of medications utilized to treat PD, such as impulse control problems; appreciation of the natural history of PD with the increasing impairments as the disease relentlessly worsens over time; the many controlled clinical trials attempting to slow the progression of the disease and to provide new symptomatic therapies; and surgical approaches to alleviate symptoms and progression, including cellular and gene therapy as well as deep brain stimulation. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: None to report.</note><note type="content">*On the occasion of the Parkinson's Disease Foundation's 50th Anniversary Educational Symposium, October 11–12, 2007, New York, NY</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>research</topic><topic>genetics</topic><topic>pathogenesis</topic><topic>epidemiology</topic><topic>imaging</topic><topic>therapy</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><name type="personal"><namePart type="given">Fahn</namePart><namePart type="family">Stanley</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Marder</namePart><namePart type="family">Karen</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Côté</namePart><namePart type="family">Lucien</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Reich</namePart><namePart type="family">Stephen G.</namePart><namePart type="termsOfAddress">MD</namePart></name><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Introduction</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="title"><title>Frontiers of Science and Clinical Advances in Quality of Life in Parkinson's Disease</title></detail><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>S1</number></detail><extent unit="pages"><start>S2</start><end>S14</end><total>13</total></extent></part></relatedItem><identifier type="istex">FBDBCDC2B8E5271B76D0026C202293F30969C97F</identifier><identifier type="DOI">10.1002/mds.22796</identifier><identifier type="ArticleID">MDS22796</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000021 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000021 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:FBDBCDC2B8E5271B76D0026C202293F30969C97F
|texte= Parkinson's disease: 10 years of progress, 1997–2007
}}
| This area was generated with Dilib version V0.6.23. |  |